This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Boone Capital disclosed a new 13F position of 398,482 TYRA shares (~$10.48M), representing 3.3% of its reportable AUM as of 12/31/2025. TYRA shares were $38.67 (up ~253% Y/Y and ~47% since quarter-end), market cap ~$2.1B; the company had ~$256M in cash (runway into 2027) but a TTM net loss of ~$120M, making the stake opportunistic and not among Boone's top five holdings.

Analysis

An institutional-sized new stake in a small-cap, binary biotech typically does more than signal fundamental conviction — it changes market mechanics around that name. Reduced available borrow and the prospect of follow-on purchases from other managers or allocators can compress implied volatility and steepen the call skew, making directional long-dated call exposure relatively cheaper on a risk-adjusted basis than buying outright equity into a readout.

From a competitive angle, FGFR-focused programs live in a narrow window where a single clean Phase 2 can convert into outsized M&A optionality because big pharm values de-risked, mechanism-specific assets highly; conversely, a safety or efficacy miss invites rapid derating and raises the probability of dilutive financings that transfer value away from current shareholders. The company’s platform/licensing optionality is the nonlinear lever here — partnership milestones can materially revalue shares without U.S. commercialization.

Key risks are binary clinical outcomes, cash-burn-driven dilution, and momentum fads that reverse faster than fundamentals can reassert themselves; expect most positive moves to occur in the 1–12 month window around trial readouts or partnership announcements, while structural downside can unfold over 12–24 months if multiple programs falter. Technically, watch borrow availability, short interest dynamics and options skew as they will amplify moves and create asymmetric payoffs for nimble option strategies.

Key Decisions for Investors

• Long-event call spread (TYRA): Buy 12-month TYRA call spread (e.g., buy Jan-2027 $40 call / sell Jan-2027 $80 call) sized to 0.25% portfolio risk. Rationale: caps premium, retains >3x upside to break-even on a positive Phase 2/M&A signal; mute vega by selling the wings. Stop loss: cut if the spread loses 50% of premium or if company announces unexpected safety signal.
• Pair trade to isolate idiosyncratic upside: Go long TYRA equity (size 0.5% portfolio) and short XBI (size to neutralize 60–70% beta) for a 6–12 month horizon. Rationale: captures potential idiosyncratic re-rating while hedging sector/systematic risk; reduce exposure if XBI outperforms or if TYRA fails first interim readout.
• Event-protected equity entry: Acquire TYRA shares ahead of an expected readout but simultaneously buy 6–9 month puts at ~30% OTM to cap downside — target net entry risk ~1% portfolio. Rationale: preserves upside participation while limiting dilution/tail-event loss; unwind protection after positive topline or if implied vol collapses.
• Volatility arbitrage (short near-term calls): If implied vol spikes after a retail-driven run, sell 30–60 day call spreads to capture premium with defined risk; avoid during announced readouts or when borrow becomes constrained. Rationale: captures mean reversion in IV and funds carry costs — keep exposure small and strictly defined-risk.